Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.045
-0.075 (-2.40%)
At close: Nov 20, 2024, 4:00 PM
3.190
+0.145 (4.76%)
After-hours: Nov 20, 2024, 6:27 PM EST
Anixa Biosciences Revenue
In the fiscal year ending October 31, 2023, Anixa Biosciences had annual revenue of $210.00K.
Revenue (ttm)
$210.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
97.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Quipt Home Medical | 244.23M |
Akoya Biosciences | 86.82M |
Assembly Biosciences | 28.33M |
Quantum-Si incorporated | 2.27M |
Adagene | 815.75K |
InflaRx | 187.93K |
INmune Bio | 42.00K |
ANIX News
- 3 days ago - Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 12 days ago - Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 15 days ago - Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 21 days ago - Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - PRNewsWire
- 24 days ago - Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 5 weeks ago - Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 6 weeks ago - Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - PRNewsWire
- 7 weeks ago - Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - PRNewsWire